Viscosupplementation vs. PRP for Knee Osteoarthritis in NYC: Which Is Right for You?

RHPNY·July 8, 2026·3 min read

Two Injection Options for Knee Osteoarthritis: Making an Evidence-Based Choice

Knee osteoarthritis is one of the most common musculoskeletal conditions in adults over 40, affecting an estimated 14 million Americans. When conservative management has been exhausted and a patient wants to avoid or delay knee replacement surgery, two intra-articular injection options are frequently recommended: viscosupplementation with hyaluronic acid (HA) and platelet-rich plasma (PRP).

At Regen Health Physicians NYC, we help patients understand the evidence behind each approach and make informed decisions. These are not interchangeable treatments—they have different mechanisms, different levels of supporting evidence, and different patient profiles.

What Is Viscosupplementation?

Viscosupplementation involves injecting hyaluronic acid—a naturally occurring component of joint fluid—directly into the knee joint. HA provides lubrication and shock absorption. In osteoarthritic joints, endogenous HA is degraded and its molecular weight is lower, reducing its biomechanical function.

Commercial HA preparations (Hyalgan, Supartz, Synvisc, Euflexxa) aim to supplement this depleted joint fluid. They are FDA-approved for knee osteoarthritis and have been used for over two decades.

What the Evidence Shows

Meta-analyses have consistently found that HA injections produce statistically significant pain reduction compared to placebo—but effect sizes are often small. The OARSI guidelines conditionally recommend HA for knee OA in certain patient subgroups. Benefits typically last 3-6 months, and HA does not stop or reverse cartilage degradation.

What Is PRP Therapy?

Platelet-rich plasma (PRP) is produced by centrifuging the patient's own blood to concentrate platelets containing growth factors including PDGF, VEGF, TGF-β, IGF-1, and FGF. When injected into the knee joint, these growth factors stimulate chondrocyte proliferation, reduce inflammatory cytokines, and promote the synovial environment supporting cartilage health.

Our regenerative medicine practice in NYC offers image-guided PRP knee injections using ultrasound guidance for precise intra-articular placement.

What the Evidence Shows

PRP has accumulated a strong evidence base for knee osteoarthritis, with multiple randomized controlled trials demonstrating:

PRP produces greater pain reduction and functional improvement than viscosupplementation at 6 and 12 months in several head-to-head trials
PRP shows greater superiority in younger patients and those with less advanced OA
PRP's anti-inflammatory mechanism may slow OA progression—a potential disease-modifying effect not seen with HA
Duration of benefit is typically 9-18 months

A 2021 network meta-analysis in the Journal of Bone and Joint Surgery ranked PRP above HA in efficacy for knee OA.

Head-to-Head Comparison

| Factor | Viscosupplementation (HA) | PRP | |--------|--------------------------|-----| | Mechanism | Lubrication, anti-inflammatory | Growth factors, chondroprotection | | Evidence level | Moderate (FDA-approved) | Strong and growing | | Typical benefit duration | 3-6 months | 9-18 months | | Disease modification potential | No | Emerging evidence | | Insurance coverage | Often covered | Typically not covered |

Which Patients Respond Best to Each?

Viscosupplementation is preferred for:

Patients with mild OA primarily needing lubrication
Patients for whom insurance coverage is a primary consideration

PRP is preferred for:

Patients with mild-to-moderate OA wanting longer-lasting relief
Patients who have received HA with suboptimal response
Active patients and athletes wanting a biologically active treatment
Patients interested in potential chondroprotective effects

Neither is appropriate for:

Severe, end-stage OA with significant bone-on-bone degeneration

The RHPNY Approach

For patients with grade 2-3 OA who are candidates for PRP, we recommend PRP knee injection with ultrasound guidance as the preferred first-line injection therapy based on current evidence. We also evaluate whether concurrent peptide therapy may enhance the systemic regenerative environment supporting knee recovery.

Book a consultation with our regenerative orthopedic team in New York City to discuss your knee OA and treatment options.

Medical Disclaimer: Intra-articular injections should be evaluated and performed by a qualified physician. This article is for educational purposes only. Results vary by individual and disease severity.